Sarepta Therapeutics | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Acadia Pharmaceuticals USD 237.8M 72.86M 2024-12
Agios Pharmaceuticals USD 9.47M 1.29M 2024-12
Alnylam Pharmaceuticals USD 490.35M 75.33M 2024-12
Amgen USD 5.97B 781M 2024-12
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 611.17M 53.89M 2024-12
Daiichi Sankyo JPY 356.46B 7.93B 2024-12
Eli Lilly USD 11.13B 1.86B 2024-12
Gilead Sciences USD 5.99B 17M 2024-12
Incyte USD 1.1B 38.34M 2024-12
Insmed USD 78.29M 6.04M 2024-12
Ionis Pharmaceuticals USD 222.75M 90M 2024-12
Moderna USD 420M 1.14B 2024-12
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Pfizer USD 12.11B 718M 2024-12
PTC Therapeutics USD 196.89M 10.95M 2024-12
Regeneron Pharmaceuticals USD 3.22B 1.88B 2024-12
Roche Holding CHF 11.69B 48M 2024-12
Sanofi EUR 10.07B 2.1B 2024-09
Sarepta Therapeutics USD 526.11M 150.63M 2024-12
Ultragenyx Pharmaceutical USD 147.98M 29.51M 2024-12
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12



Sarepta Therapeutics Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.